Physician profile
John E Fitzpatrick
NPI 1699740753
$1,608.94
in general payments reported to CMS, 2019-2025
16 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $97.23 · 2021: $425 · 2022: $319 · 2023: $177 · 2024: $46.70 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $630.53 | 2019-2025 | |
| Abbvie INC. | $309.06 | 2021-2025 | |
| Emd Serono, INC. | $138.54 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $134.84 | 2019-2020 | |
| Ucb, INC. | $129.25 | 2025 | Briviact, Fintepla, Nayzilam |
| Abbott Laboratories | $42.13 | 2022-2023 | Infinity |
| Allergan, INC. | $40.64 | 2020-2021 | |
| Amgen INC. | $34.47 | 2019 | |
| Pfizer INC. | $33.72 | 2023 | |
| Boston Scientific Corporation | $31.17 | 2024 | Varithena Administration Pack |
| Teva Pharmaceuticals USA, INC. | $15.53 | 2024 | Austedo Xr |
| Acadia Pharmaceuticals INC | $14.92 | 2019 | |
| Mdd US Operations, LLC | $14.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.85 | 2020 | |
| Biogen, INC. | $13.77 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.